Home · Reading room · Your questions

Your questions

Wegovy and endometriosis: what the early research shows, and what it can’t

People with endo are talking about Wegovy online. The research is younger than the conversation, and it is worth reading slowly.

Havelle editorial · Education only, not medical advice · Reviewed September 2026

The short answer: Wegovy (semaglutide) is not approved to treat endometriosis, and no GLP-1 medication has been shown in a clinical trial to treat the disease. What exists so far is early: a 2026 international survey in which people with endometriosis who used a GLP-1 described their own symptoms, plus laboratory and case-report work. That is a reason for researchers to run proper trials. It is not a reason for any provider to prescribe Wegovy, or tirzepatide, as endometriosis care.

Why this question is everywhere right now

Search “Wegovy endometriosis” and you will find forum threads, podcast episodes and clinic blogs, many of them hopeful. The hope makes sense. Endometriosis care is slow, treatment options are limited, and anyone who has lived with the pain for years will pay attention when other patients say something helped.

So the question deserves a straight answer rather than a brush-off. The straight answer has two parts: what has been reported, and what those reports can and cannot tell you.

What has been reported

The largest piece of evidence so far is an international survey from a research team at McMaster University in Canada, posted in 2026 as a preprint (meaning it had not yet completed peer review when it appeared). The team asked people with confirmed or suspected endometriosis who had used a GLP-1 medication to rate how their symptoms changed. About three in four were on semaglutide and about one in five on tirzepatide.

Roughly 65% reported improvement in at least one endometriosis-related symptom, most often bloating, followed by lower back pain and pelvic pain outside of periods. The same respondents also reported average weight loss of around 12 kilograms, and greater weight loss tracked with greater improvement in overall quality of life.

Alongside the survey sit a small number of laboratory studies on inflammation pathways and individual case reports. None of this is a clinical trial.

Why those findings are limited

A survey like this can point researchers somewhere. It cannot show cause. Three reasons, in plain terms:

The honest reading is that the survey justifies a proper randomised trial. Until one reports, GLP-1 medications are not a treatment for endometriosis, and the pain, the lesions and the disease itself remain the work of your gynecologist or endometriosis specialist.

An early signal is a reason to study something. It is not a reason to sell it.

Wegovy, Ozempic, Zepbound, compounded: sorting the names

Wegovy and Ozempic are both semaglutide. Zepbound and Mounjaro are both tirzepatide. Most telehealth GLP-1 programs, including the thirteen Havelle reviews, prescribe tirzepatide, usually compounded. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety or efficacy, and findings about the branded products do not automatically carry over to a compounded version.

One difference matters for many people with endometriosis, since so many manage it with hormonal medication taken by mouth. The tirzepatide label advises anyone on an oral hormonal contraceptive to switch to a non-oral method, or add a barrier method, for four weeks after starting and for four weeks after each dose increase. If your endometriosis plan includes an oral hormonal medication, bring it up before your first dose. We walk through that conversation in our guide to hormone therapy and GLP-1s.

What to ask a provider who brings it up

If a GLP-1 program mentions endometriosis at all, listen to how. A careful provider says something like: “This is for weight and metabolic health. It is not endometriosis treatment, and we will coordinate with the person managing your endo.” A provider who suggests the medication will treat the disease is telling you how they will handle everything else, too.

That is exactly what the third promise of the Whole-Woman Charter measures: honest framing of metabolic support, never presented as endometriosis treatment. Three of the thirteen providers we review reach our top tier across all seven promises: Alloy Women’s Health ($199/mo), Emerge Weight Loss ($224/mo) and Gaya Wellness ($399/mo), listed alphabetically. No provider pays for placement.

If you take one thing from this page. The early reports are interesting and worth following. They are not evidence that Wegovy or any GLP-1 treats endometriosis, and any program that sells it that way has answered the most important question for you.

Five questions to ask any GLP-1 provider →